Phase II And III Trials Of Covaxine On Children Soon

Phase II and III trials of covaxine on children soon. Another anti-corona vaccine trial for children is about to begin in the country.

Pune-based Serum Institute of India (SII), the world’s largest vaccine manufacturer, has started recruiting volunteers from Sunday for its Kovovax vaccine.

The Drugs Controller General of India (DCGI) had approved the serum for Phase II and III trials of Kovovax in July itself.

Official sources said that the company will test it on 920 children in the age group of 2-17 years at 10 locations in the country. It will cover 460-460 children in the age group of 2-11 and 12-17 years.

Earlier, the country’s drug regulator has approved the emergency use of Zydus Cadila’s Zycov-D for children.

This indigenous vaccine of Zydus will be administered to children in the age group of 12-18 years. This is the country’s first vaccine for children.

In the application given here by DCGI, it has been said on behalf of SII that at present, people above 18 years of age are being vaccinated all over the world.

Children will be at increased risk of contracting the coronavirus after adults are vaccinated. Even in the third wave, children are expected to be affected the most.

The company has also said that until the children are also not vaccinated, the coronavirus may not be eradicated. Until the virus is not eradicated, the danger for everyone will remain.

Bharat Biotech looking for an international partner to address the shortage of vaccine

Indigenous covaxine maker Bharat Biotec is looking for international manufacturing partners to meet its target of producing one billion doses of the COVID-19 vaccine every year.

The government was expected to deliver 6 crores to 70 million Covaxine doses monthly from Bharat Biotech in July and August, which the company could not fulfill.

The company had delivered only 25 million doses last month. Now the company is looking for international partners to fulfill its promise.

The first batch of vaccine shots was dispatched from the company’s plant at Ankleshwar, Gujarat on Sunday. The plant has the capacity to produce more than 10 million doses per month.

Bharat Biotech said it is exploring opportunities with its international partners.

“We want to ensure that India Biotech can fully meet the demand for the vaccine so that the vaccine can reach people in the country and around the world.”

The company’s chairman and managing director Krishna Ella said in a statement.